|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5555590||1403080||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- Heart failure was not responsive to glucocorticoid and immunosuppressive therapy in an EGPA male patient.
- Cardiac function significantly improved after adding high dose IVIG therapy.
- High dose IVIG therapy was required to maintain a sustained remission of the heart failure.
Glucocorticoids and immunosuppressive drugs represent the first-line treatment of eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss syndrome), even though the combined therapy is not successful in achieving the disease remission in some patients with neurological or cardiac involvement. We describe a case of an EGPA male patient with impaired left ventricular function not responsive to glucocorticoid and immunosuppressive therapy. We observed that high-dose (2Â g/kg/4Â weeks) intravenous immunoglobulin (IVIG) therapy significantly improved cardiac function, which was deteriorated after reducing IVIG dose at 0.5Â g/kg/4Â weeks, and was restored increasing again IVIG dose to 2Â g/kg/4Â weeks. The finding highlights the relevance of IVIG as treatment of choice in EGPA patients with cardiac involvement not responsive to the standard glucocorticoid and immunosuppressive therapy. Moreover, at a follow-up of 24Â months, the continuance of high dose IVIG therapy was required to maintain a sustained remission of the heart failure.
Journal: International Immunopharmacology - Volume 45, April 2017, Pages 13-15